Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Carcinoma, Non-Small-Cell Lung"" wg kryterium: Temat


Tytuł:
A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
Autorzy:
Li Y; Department of Radiology, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Lv X; Department of Radiology, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China.
Chen C; Institute of Advanced Research, Infervision Medical Technology Co., Ltd., Beijing, 100025, China.
Yu R; Institute of Advanced Research, Infervision Medical Technology Co., Ltd., Beijing, 100025, China.
Wang B; Department of Radiology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, China.
Wang D; Institute of Advanced Research, Infervision Medical Technology Co., Ltd., Beijing, 100025, China. .
Hou D; Department of Radiology, Beijing Chest Hospital, Capital Medical University, Beijing, 101149, China. .
Pokaż więcej
Źródło:
European radiology experimental [Eur Radiol Exp] 2024 Jan 02; Vol. 8 (1), pp. 2. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnostic imaging
Carcinoma, Non-Small-Cell Lung*/genetics
Deep Learning*
Lung Neoplasms*/diagnostic imaging
Lung Neoplasms*/genetics
Brain Neoplasms*/diagnostic imaging
Brain Neoplasms*/genetics
Humans ; Retrospective Studies ; Magnetic Resonance Imaging ; ErbB Receptors/genetics ; Mutation
Czasopismo naukowe
Tytuł:
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Autorzy:
Kato T; Department of Thoracic Oncology, Kanagawa Cancer Center, Asahi Ward, Yokohama, Japan. Electronic address: .
Casarini I; Servicio Oncología, Hospital Bernardo Houssay, Mar del Plata, Buenos Aires, Argentina.
Cobo M; Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain.
Faivre-Finn C; University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.
Hegi-Johnson F; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Lu S; Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
Özgüroğlu M; Department of Internal Medicine, Division of Medical Oncology, Clinical Trial Unit, Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey.
Ramalingam SS; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA.
Pokaż więcej
Źródło:
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2024 Jan; Vol. 187, pp. 107414. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Retrospective Studies ; Protein Kinase Inhibitors/pharmacology ; ErbB Receptors/genetics ; Mutation/genetics
Czasopismo naukowe
Tytuł:
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
Autorzy:
Niu L; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.
Wu H; Department of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Jishou, 416000, China.
Gao R; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.
Chen L; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.
Wang J; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.
Duan H; Department of Oncology, Xiangxi Autonomous Prefecture People's Hospital, Jishou, 416000, China.
Long Y; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.
Xie Y; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China.
Zhou Q; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China. .
Zhou R; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Road, Kaifu District, Changsha, 410008, Hunan, China. .; Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, 410008, China. .; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 19; Vol. 150 (2), pp. 94. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Prospective Studies ; Protein Kinase Inhibitors/therapeutic use ; ErbB Receptors/genetics ; Retrospective Studies ; Mutation
Czasopismo naukowe
Tytuł:
TEP RNA: a new frontier for early diagnosis of NSCLC.
Autorzy:
Wang Y; Clinical Laboratory, The First Affiliated Hospital of Weifang Medical University (Weifang People's Hospital), Weifang Medical University, Weifang, 261000, Shandong, China.; Department of Clinical Laboratory Science, Weifang Medical University, Weifang, 261000, Shandong, China.
Dong A; Clinical Laboratory, The First Affiliated Hospital of Weifang Medical University (Weifang People's Hospital), Weifang Medical University, Weifang, 261000, Shandong, China.
Jin M; Clinical Laboratory, The First Affiliated Hospital of Weifang Medical University (Weifang People's Hospital), Weifang Medical University, Weifang, 261000, Shandong, China.; Department of Clinical Laboratory Science, Weifang Medical University, Weifang, 261000, Shandong, China.
Li S; Clinical Laboratory, The First Affiliated Hospital of Weifang Medical University (Weifang People's Hospital), Weifang Medical University, Weifang, 261000, Shandong, China. .
Duan Y; Clinical Laboratory, The First Affiliated Hospital of Weifang Medical University (Weifang People's Hospital), Weifang Medical University, Weifang, 261000, Shandong, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 19; Vol. 150 (2), pp. 97. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnosis
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Humans ; Early Detection of Cancer ; Carcinogenesis ; Cell Transformation, Neoplastic ; Biomarkers
Czasopismo naukowe
Tytuł:
Efficacy of bevacizumab through an indwelling pleural catheter in non-small cell lung cancer patients with symptomatic malignant pleural effusion.
Autorzy:
Zeng H; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China.
Zhang Y; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China.
Tan S; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China.
Huang Q; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China.
Pu X; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China.
Tian P; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China. .; Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, China. .
Li Y; Lung Cancer Center/Lung Cancer Institute, West China Hospital , Sichuan University, No. 37 GuoXue Alley, 610041, Chengdu, Sichuan Province, China. .; Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, 610041, Chengdu, Sichuan, China. .
Pokaż więcej
Źródło:
BMC pulmonary medicine [BMC Pulm Med] 2024 Feb 16; Vol. 24 (1), pp. 89. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/complications
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Pleural Effusion, Malignant*/etiology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Male ; Humans ; Middle Aged ; Bevacizumab/therapeutic use ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; Catheters, Indwelling/adverse effects
Czasopismo naukowe
Tytuł:
The novel miR-873-5p-YWHAE-PI3K/AKT axis is involved in non-small cell lung cancer progression and chemoresistance by mediating autophagy.
Autorzy:
Li Z; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050000, China.
Liu J; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050000, China.
Wang P; Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
Zhang B; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050000, China.
He G; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050000, China.
Yang L; Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050000, China. .
Pokaż więcej
Źródło:
Functional & integrative genomics [Funct Integr Genomics] 2024 Feb 16; Vol. 24 (2), pp. 33. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
MicroRNAs*/genetics
MicroRNAs*/metabolism
Male ; Female ; Humans ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Drug Resistance, Neoplasm/genetics ; Gefitinib ; Cell Line, Tumor ; Autophagy/genetics ; Cell Proliferation/genetics ; 14-3-3 Proteins/genetics ; 14-3-3 Proteins/metabolism
Czasopismo naukowe
Tytuł:
CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
Autorzy:
Wang J; School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.
Wang J; School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China.; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.
Huang X; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China.
Zhou Y; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China.
Qi J; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.; University of Science and Technology of China, Hefei, Anhui, China.
Sun X; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.; University of Science and Technology of China, Hefei, Anhui, China.
Nie J; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China.
Hu Z; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China.; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China.
Wang S; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China. .
Hong B; School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China. .; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China. .; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China. .
Wang H; School of Basic Medical Sciences, Anhui Medical University, Hefei, Anhui, China. .; Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui, China. .; Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, Anhui, China. .
Pokaż więcej
Źródło:
BMC medical imaging [BMC Med Imaging] 2024 Feb 15; Vol. 24 (1), pp. 45. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnostic imaging
Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/diagnostic imaging
Lung Neoplasms*/therapy
Lung Neoplasms*/pathology
Humans ; Retrospective Studies ; Radiomics ; Tomography, X-Ray Computed/methods ; Biomarkers, Tumor ; Immunotherapy
Czasopismo naukowe
Tytuł:
The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab.
Autorzy:
Leshem Y; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Etan T; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Dolev Y; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Nikolaevski-Berlin A; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Miodovnik M; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Shamai S; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Merimsky O; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Wolf I; Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Havakuk O; Division of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Tzuberi M; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Topilsky Y; Division of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Banai S; Division of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rozenbaum Z; Division of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Tulane University, New Orleans, LA, United States of America.
Laufer-Perl M; Division of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: .
Pokaż więcej
Źródło:
International journal of cardiology [Int J Cardiol] 2024 Feb 15; Vol. 397, pp. 131642. Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnosis
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/diagnosis
Lung Neoplasms*/drug therapy
Atrial Fibrillation*
Antibodies, Monoclonal, Humanized*
Humans ; Prognosis ; Retrospective Studies ; Adrenergic beta-Antagonists/therapeutic use
Czasopismo naukowe
Tytuł:
Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
Autorzy:
Huang DD; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Yang JC; Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2024 Feb 12; Vol. 42 (2), pp. 172-174.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Carcinoma, Squamous Cell*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Epithelial Cells
Czasopismo naukowe
Tytuł:
Radiation pneumonitis after concurrent aumolertinib and thoracic radiotherapy in EGFR-mutant non-small cell lung cancer patients.
Autorzy:
Yin H; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.
Jia W; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117, China.; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Wuhan, 430022, Hubei, China.
Yu J; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, 250117, Shandong, China. .
Zhu H; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, 250117, Shandong, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 12; Vol. 24 (1), pp. 197. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/radiotherapy
Radiation Pneumonitis*/epidemiology
Radiation Pneumonitis*/etiology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/radiotherapy
Acrylamides*
Indoles*
Pyrimidines*
Humans ; Retrospective Studies ; Radiotherapy Dosage ; ErbB Receptors/genetics
Czasopismo naukowe
Tytuł:
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
Autorzy:
Kuribayashi T; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Ohashi K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan. .
Nishii K; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Ninomiya K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Tsubata Y; Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Faculty of Medicine, Shimane University, Izumo, Japan.
Ishikawa N; Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Kodani M; Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Kanaji N; Department of Internal Medicine, Division of Hematology, Rheumatology, and Respiratory Medicine, Faculty of Medicine, Kagawa University, Miki, Kagawa, Japan.
Yamasaki M; Department of Respiratory Medicine, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
Fujitaka K; Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kuyama S; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan.
Takigawa N; Department of Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Fujimoto N; Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
Kubota T; Department of Respiratory Medicine and Allergology, Kochi University Hospital, Kochi, Japan.
Inoue M; Department of Chest Surgery, Shimonoseki City Hospital, Shimonoseki, Japan.
Fujiwara K; Department of Respiratory Medicine, NHO Okayama Medical Center, Okayama, Japan.
Harita S; Department of Internal Medicine, Okayama Saiseikai General Hospital, Okayama, Japan.
Takata I; Internal Medicine, Fukuyama City Hospital, Fukuyama, Japan.
Takada K; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Okawa S; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.; Internal Medicine, Kajiki Hospital, Okayama, Japan.
Hotta K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 12; Vol. 150 (2), pp. 89. Date of Electronic Publication: 2024 Feb 12.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Male ; Aged ; Female ; Immune Checkpoint Inhibitors/therapeutic use ; Prospective Studies ; Retrospective Studies ; Neoplasm Recurrence, Local/drug therapy ; ErbB Receptors/genetics ; Mutation ; Lung/pathology
Czasopismo naukowe
Tytuł:
Coexpression of TP53, BIM, and PTEN Enhances the Therapeutic Efficacy of Non-Small-Cell Lung Cancer.
Autorzy:
Lu L; State Key Laboratory of Elemento-Organic Chemistry and Department of Chemical Biology, National Engineering Research Center of Pesticide (Tianjin), College of Chemistry, Nankai University, Tianjin 300071, China.
Ma D; State Key Laboratory of Elemento-Organic Chemistry and Department of Chemical Biology, National Engineering Research Center of Pesticide (Tianjin), College of Chemistry, Nankai University, Tianjin 300071, China.
Xi Z; State Key Laboratory of Elemento-Organic Chemistry and Department of Chemical Biology, National Engineering Research Center of Pesticide (Tianjin), College of Chemistry, Nankai University, Tianjin 300071, China.
Pokaż więcej
Źródło:
Biomacromolecules [Biomacromolecules] 2024 Feb 12; Vol. 25 (2), pp. 792-808. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/therapy
Lung Neoplasms*/drug therapy
Mice ; Animals ; Humans ; Cell Line, Tumor ; PTEN Phosphohydrolase/genetics ; PTEN Phosphohydrolase/metabolism ; PTEN Phosphohydrolase/pharmacology ; Apoptosis/genetics ; Tumor Suppressor Protein p53/genetics
Czasopismo naukowe
Tytuł:
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
Autorzy:
Memon D; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK; M:M Bio Limited, 99 Park Drive, Milton, Abingdon, UK.
Schoenfeld AJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Ye D; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation, University of Pennsylvania, Philadelphia, PA, USA.
Fromm G; Shattuck Labs, Durham, NC, USA.
Rizvi H; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Early Clinical Development, Oncology R&D, AstraZeneca, New York, NY, USA.
Zhang X; Data Sciences and Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Keddar MR; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK.
Mathew D; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute for Immunology and Immune Health, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Yoo KJ; Shattuck Labs, Durham, NC, USA.
Qiu J; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation, University of Pennsylvania, Philadelphia, PA, USA.
Lihm J; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Miriyala J; Shattuck Labs, Durham, NC, USA.
Sauter JL; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luo J; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chow A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Bhanot UK; Precision Pathology Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
McCarthy C; Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vanderbilt CM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Liu C; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Abu-Akeel M; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Plodkowski AJ; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
McGranahan N; Cancer Genome Evolution Research Group, University College London Cancer Institute, London, UK.
Łuksza M; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Greenbaum BD; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Merghoub T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA; Parker Institute for Cancer Immunotherapy, MSK, New York, NY, USA; Human Oncology and Pathogenesis Program, MSK, New York, NY, USA.
Achour I; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
Barrett JC; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
Stewart R; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
Beltrao P; European Molecular Biology Laboratory (EMBL), European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK; Institute of Molecular Systems Biology, ETH Zürich, Zurich, Switzerland.
Schreiber TH; Shattuck Labs, Durham, NC, USA.
Minn AJ; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Mark Foundation Center for Immunotherapy, Immune Signaling, and Radiation, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: .
Miller ML; Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, UK; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK. Electronic address: .
Hellmann MD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA; Early Clinical Development, Oncology R&D, AstraZeneca, New York, NY, USA; Parker Institute for Cancer Immunotherapy, MSK, New York, NY, USA. Electronic address: .
Pokaż więcej
Źródło:
Cancer cell [Cancer Cell] 2024 Feb 12; Vol. 42 (2), pp. 209-224.e9. Date of Electronic Publication: 2024 Jan 11.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Humans ; Animals ; Mice ; Signal Transduction ; Immunotherapy ; Antigen Presentation ; B7-H1 Antigen/metabolism ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
Autorzy:
Zhou C; Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: .
Hu Y; Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430000, China.
Arkania E; LTD Israeli-Georgian Medical Research Clinic 'Helsicore', Tbilisi 0112, Georgia.
Kilickap S; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.
Ying K; Department of Pneumology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China.
Xu F; Department of Pneumology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Wu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.
Wang X; Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 221009, China.
Viguro M; Clinical Research Department, Medical Center 'Mriya Med-Service', Kryvyi Rih 50000, Ukraine.
Makharadze T; LTD 'High Technology Hospital MedCenter', Batumi 6010, Georgia.
Sun H; Department of Medical Oncology, Jiamusi Cancer Hospital, Jiamusi 154007, China.
Luo F; Lung Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China.
Shi J; Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276000, China.
Zang A; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China.
Pan Y; Department of Medical Oncology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China.
Chen Z; Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Jia Z; Department of Oncology, Linyi People's Hospital, Linyi 276002, China.
Kuchava V; LTD Institute of Clinical Oncology, Tbilisi 0159, Georgia.
Lu P; Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China.
Zhang L; Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China.
Cheng Y; Department of Oncology, Jilin Cancer Hospital, Changchun 130012, China.
Kang W; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.
Wang Q; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.
Yu H; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.
Li J; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.
Zhu J; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.
Pokaż więcej
Corporate Authors:
ASTRUM-004 Investigators
Źródło:
Cancer cell [Cancer Cell] 2024 Feb 12; Vol. 42 (2), pp. 198-208.e3. Date of Electronic Publication: 2024 Jan 04.
Typ publikacji:
Clinical Trial, Phase III; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Carcinoma, Squamous Cell*/drug therapy
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Paclitaxel/adverse effects ; Carboplatin/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Immune Checkpoint Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis.
Autorzy:
Wang Y; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, 710061, Shanxi, Xi'an, Shanxi, P.R. China.; Department of Thoracic Surgery, The Affiliated Hospital of Inner Mongolia Medical University, 010050, Hohhot, Inner Mongolia, P.R. China.
Ren H; Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 West Yanta Road, 710061, Shanxi, Xi'an, Shanxi, P.R. China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 08; Vol. 24 (1), pp. 187. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Recombinant Proteins*
Endostatins*
Humans ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Multiomics ; Vascular Endothelial Growth Factor A/metabolism ; Cell Line, Tumor ; Methyltransferases/genetics
Czasopismo naukowe
Tytuł:
CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
Autorzy:
Fan X; Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China.; Medical School of Nantong University, Nantong University, Nantong, China.; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
Zhang Q; Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China.; Medical School of Nantong University, Nantong University, Nantong, China.; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
Qin S; Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China.; Medical School of Nantong University, Nantong University, Nantong, China.; Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, Jiangsu, China.
Ju S; Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, 226001, Jiangsu, China. .; Department of Laboratory Medicine, Affiliated Hospital of Nantong University, No. 20, Xisi Road, Nantong, 226001, Jiangsu, China. .
Pokaż więcej
Źródło:
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 Feb 08; Vol. 150 (2), pp. 83. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnosis
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/diagnosis
Lung Neoplasms*/genetics
Humans ; In Situ Hybridization, Fluorescence ; RNA, Circular/genetics ; Biomarkers
Czasopismo naukowe
Tytuł:
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition.
Autorzy:
Li Y; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Wang P; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China.
Xu J; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Shi X; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Yin T; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Teng F; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, People's Republic of China.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China.
Pokaż więcej
Źródło:
Oncoimmunology [Oncoimmunology] 2024 Feb 07; Vol. 13 (1), pp. 2312628. Date of Electronic Publication: 2024 Feb 07 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/diagnostic imaging
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/diagnostic imaging
Lung Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Radiomics ; Retrospective Studies ; Disease Progression ; Biomarkers
Czasopismo naukowe
Tytuł:
ADAMTS Gene-Derived circRNA Molecules in Non-Small-Cell Lung Cancer: Expression Profiling, Clinical Correlations and Survival Analysis.
Autorzy:
Pietrzak J; Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.; BRaIn Laboratories, Medical University of Lodz, Czechoslowacka 4, 92-216 Lodz, Poland.
Świechowski R; Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.; BRaIn Laboratories, Medical University of Lodz, Czechoslowacka 4, 92-216 Lodz, Poland.
Wosiak A; Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.; BRaIn Laboratories, Medical University of Lodz, Czechoslowacka 4, 92-216 Lodz, Poland.
Wcisło S; Department of Thoracic, General and Oncological Surgery, Medical University of Lodz and Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz - Central Veteran Hospital, 90-542 Lodz, Poland.
Balcerczak E; Laboratory of Molecular Diagnostics and Pharmacogenomics, Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.; BRaIn Laboratories, Medical University of Lodz, Czechoslowacka 4, 92-216 Lodz, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 05; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
MicroRNAs*
Humans ; RNA, Circular/genetics ; Metalloendopeptidases ; Survival Analysis ; Cell Proliferation ; ADAMTS Proteins/genetics
Czasopismo naukowe
Tytuł:
Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South Korea.
Autorzy:
Jung HA; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Lim SM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Yu H; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yoon S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim D; Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea.; Department of Family Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Kim KP; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Jeong H; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Doh H; Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea.
Lim S; Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, South Korea.
Kim J; IQVIA Solutions, Real World Solutions-Korea, Seoul, South Korea.
Zhao X; IQVIA Solutions, Real World Solutions-Asia Pacific, Singapore.
Horsburgh D; IQVIA Solutions, Real World Solutions-Asia Pacific, Singapore.
Patel D; IQVIA Solutions, Real World Solutions-Global, London, United Kingdom.
Kim JA; IQVIA Solutions, Real World Solutions-Korea, Seoul, South Korea.
Toh KC; IQVIA Solutions, Real World Solutions-Asia Pacific, Singapore.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2024 Feb 05; Vol. 7 (2), pp. e2355331. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/epidemiology
Lung Neoplasms*/therapy
Lung Neoplasms*/diagnosis
Carcinoma, Squamous Cell*
Male ; Humans ; Aged ; Female ; Cohort Studies ; Retrospective Studies ; Receptor Protein-Tyrosine Kinases/therapeutic use ; ErbB Receptors
Czasopismo naukowe
Tytuł:
Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
Autorzy:
Yan N; Department of Medical Oncology, Zhengzhou University First Affiliated Hospital, 1st East Jianshe Road, Zhengzhou, Henan, 450002, China.
Zhang H; Department of Medical Oncology, Zhengzhou University First Affiliated Hospital, 1st East Jianshe Road, Zhengzhou, Henan, 450002, China.
Shen S; Department of Radiation Oncology, Zhengzhou University First Affiliated Hospital, Zhengzhou, Henan, 450002, China.
Guo S; Department of Medical Oncology, Zhengzhou University First Affiliated Hospital, 1st East Jianshe Road, Zhengzhou, Henan, 450002, China. .
Li X; Department of Medical Oncology, Zhengzhou University First Affiliated Hospital, 1st East Jianshe Road, Zhengzhou, Henan, 450002, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Feb 05; Vol. 24 (1), pp. 178. Date of Electronic Publication: 2024 Feb 05.
Typ publikacji:
Journal Article
MeSH Terms:
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Retrospective Studies ; B7-H1 Antigen/genetics ; Data Analysis ; Proto-Oncogene Proteins c-ret/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies